Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV. The new investigational regimen, known as 572-Trii, will combine the investigational integrase inhibitor, S/GSK1349572 (‘572), and ViiV Healthcare’s combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC).